PlantForm Corporation

PlantForm is proud to be advancing biologics innovation with CDMO services using our cost-effective, plant-based vivoXPRESS® manufacturing platform. More info here: https://https://lnkd.in/gRcKvxqw #cdmo #biologics #biologicsmanufacturing #antibodytherapeutics #proteins #BIO2022 #LimitlessTogether

Something big is brewing across the pond ... stay tuned 👀

Read about PlantForm's game-changing tech 🌿 for #biologic drug production in Genetic Engineering & Biotechnology News 👇 Interest in molecular farming is surging, and PlantForm is on the leading edge. Our CEO Don Stewart explains how our proprietary vivoXPRESS® system makes it easier, faster, and less expensive to manufacture biologic drugs. Exciting developments include our work on a biosimilar version of the cancer drug Keytruda, in collaboration with Brazil’s Bio-Manguinhos / Fiocruz and Belgium-based SwiftPharma. ---- Follow PlantForm Corporation 🛎 for updates as we pioneer a new era in plant-based biologics #biotech #biopharmaceuticals #biosimilar #cancer https://lnkd.in/etY2chTH

Excellent meetings + industry insights at the Southern California Biomedical Council (SoCalBio) conference, where our CEO Don Stewart presented our plant-based 🌿 tech for high-value #biologic drugs. Our thanks to Mohammad E. Kondri, MPH, MIS/MBA, Trade Commissioner of Life Sciences & Medtech Industries, and the Consulate General of Canada in Los Angeles | Consulat général du Canada à Los Angeles for sponsoring this event. #SoCalBio #HealthcareInnovation #MedTech #Bioscience #biosimilars

PlantForm is pioneering a new era in plant-based #biologics, with major market opportunities on the horizon. 🌿 Our patented vivoXPRESS® platform can efficiently produce 60+ antibody and protein drugs with several key advantages. Learn more and explore investor materials at the link below:

PlantForm CEO Don Stewart will present our plant-based biopharma 🌿 opportunity at the 26th Annual SoCalBio Investor & Partnering Conference in Newport Beach, California Sept. 26. Find out how we are using our versatile, cost-effective vivoXPRESS® production system to develop important #biosimilar and medical countermeasure drugs. Presentation details: 🗓 Thursday Sept 26 ⏰ 2:00 pm (PT) See the full conference agenda: https://lnkd.in/gpXRnP7Q cc David Cayea Southern California Biomedical Council (SoCalBio) #SoCalBio #HealthcareInnovation #MedTech #Bioscience

Exciting news! We're presenting at US Capital Global's GreenTech Event in Washington, D.C. Sept. 18! Find out how PlantForm Corporation is revolutionizing plant-based biologics for global access to affordable medicines. More info and tickets here: https://lnkd.in/g3HMzddZ #biotech #biopharmaceuticals #innovation #healthtech

AntoXa Corporation and SwiftPharma will present their work to develop and commercialize a plant-made antibody treatment for #ricin exposure to the NATO Biological Defense Medical Expert Panel on Sept. 19 in Tournai, Belgium. The patented process for manufacturing the PhD9 antibody was developed by AntoXa, a PlantForm Corporation subsidiary, under license from Defence Research and Development Canada | Recherche et développement pour la défense Canada. AntoXa and SwiftPharma have a strategic collaboration agreement to accelerate advancement of the drug in European, Middle Eastern and African (EMEA) markets. SwiftPharma will use its recently completed state-of-the-art GMP manufacturing facility in Belgium to produce PhD9 for clinical trials and commercial sale. Read more: https://lnkd.in/gC-PBSAM #biopharmaceutical #biotech #antibodytherapeutics #countermeasures

📣 PlantForm is pleased to announce we've signed a Collaborative Research Agreement (CRA) with The Dabom Inc. of South Korea for joint research efforts aimed at developing artificial exosomes for therapeutic projects. The collaboration aims to establish a technology process for creating synthetic exosomes and to advance the development and commercialization of therapeutic agents through the agreement. #biotech #exosomes #researchanddevelopment

📣 New publication: The first on plant-derived 🌿 recombinant hemopexin! This research article, published in the American Journal of Physiology (Lung Cellular and Molecular Physiology), shows that AntoXa Corporation's plant-made hemopexin product functions in an identical manner to the human (serum-derived) protein. AntoXa is a PlantForm Corporation subsidiary focused on biodefense therapeutics. Hemopexin is used to treat conditions associated with high levels of heme in serum - such as exposure to halogenated compounds (e.g., chlorine and phosgene from an industrial  accident or bioterrorism), sickle-cell disease, or from a blood transfusion. The plant-made hemopexin product opens up the potential for bulk production of hemopexin as a human biotherapeutic. This is important because the only current source is derived from donor serum and recovery rates are very low. This publication is in collaboration with our research partners at University of Alabama at Birmingham. Authors: Sadis Matalon, Zhihong Yu, Shubham Dubey, Israr Ahmad, Emily M. Stephens, Ammar Saadoon Alishlash, Ashley Meyers, Doug Cossar, Don Stewart. See the article "Hemopexin reverses activation of lung eIF2α and decreases mitochondrial injury in chlorine-exposed mice" here: https://lnkd.in/gMyCEQvN cc American Physiological Society #biopharmaceuticals #biodefense #biotech #innovation